Targeting RAS-mutant cancer cells using a synthetic RAS-activated cancer killing system
{{output}}
Despite being the most commonly mutated proteins in cancer, oncogenic RAS proteins remain largely untapped as pharmacological targets. Here, we report a synthetic cancer-killing platform, termed 'RAS-activated cancer killing (RACK)' system. Leveraging a tran... ...
